Abstract
Male hypogonadism (HG) is the functional incompetence of the male gonads to produce male sex hormones and to carry out spermatogenesis. The definition of HG relies on the measurement of serum total testosterone (tT) concentrations. A recent consensus has proposed tT concentrations of about 12 nmol/L (346 ng/dL) as the lower limit of normal and 8 nmol/L (231 ng/dL) as the unequivocally low value that deserves replacement therapy. For tT values between these limits, calculation of free T (fT) may be helpful.
The most common classification is based on the topographic localization of the cause of HG at different levels of the hypothalamic-pituitary-testicular (HPT) axis. Accordingly, the cause of HG may be of hypothalamic, pituitary, or testicular origin. HG of hypothalamic or pituitary origin is referred to as “secondary,” “central,” or hypogonadotropic HG, whereas HG induced by testicular disorders is referred to as “primary” or hypergonadotropic. Certain disorders may impair the whole HPT axis and result in combined HG. Moreover, HG may be classified depending on the testicular compartment being affected, as selective, affecting either Leydig cell function or spermatogenesis, or total, affecting both. Alternatively, HG is classified according to the age at onset, as the clinical sequelae of HG can be variable in different ages. HG at early fetal life usually results in disorders of sex development, whereas onset at the end of fetal life results in mild disorders, as maldescended testes and micropenis. HG in childhood may remain undetected, until delayed puberty is suspected with persistence of sexual infantilism and appearance of eunuchoidal proportions. HG in adulthood may also be insidious, since nonspecific symptoms usually precede sexual symptoms. Finally, late-onset HG (LOH) observed among several aging men is characterized by partial T deficiency and gradual onset.
The prevalence of HG in the community is variable, as the studies that contain such data have used different age ranges or T thresholds, and is estimated to be around 6–12% among 30–70-year-old men, with a progressive increase with age. The majority of cases concerns LOH, whereas overt HG due to organic disorders is much less common. The incidence of congenital hypogonadotropic HG is 1:10,000, while that of Klinefelter syndrome, the most common chromosomal abnormality in humans, is 1 in 650 newborn males.
This is a preview of subscription content, log in via an institution.
References
Barthold JS, Gonzalez R. The epidemiology of congenital cryptorchidism, testicular ascent and orchiopexy. J Urol. 2003;170(6 Pt 1):2396.
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536.
Boddi V, Barbaro V, McNieven P, Maggi M, Rotella CM. Present and future association between obesity and hypogonadism in Italian males. Arch Ital Urol Androl. 2014;86(1):26.
Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol. 1993;39(4):417.
Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumours and radiotherapy. Pituitary. 2005;8(3–4):203.
Dohle GR. Male infertility in cancer patients: review of the literature. Int J Urol. 2010;17(4):327.
Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73(5):1016.
Hellinga G. Classification of male hypogonadism. Acta Endocrinol Suppl (Copenh). 1957;24(Suppl 31):148.
Ho CC, Singam P, Hong GE, Zainuddin ZM. Male sexual dysfunction in Asia. Asian J Androl. 2011;13(4):537.
Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen insensitivity syndrome. Lancet. 2012;380(9851):1419.
Huhtaniemi IT. LH and FSH receptor mutations and their effects on puberty. Horm Res. 2002;57(Suppl 2):35.
Jahnukainen K, Ehmcke J, Hou M, Schlatt S. Testicular function and fertility preservation in male cancer patients. Best Pract Res Clin Endocrinol Metab. 2011;25(2):287–302.
Kaltsas G, Kanakis G, Moser H. Adrenal insufficiency due to X-linked adrenoleukodystrophy. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000.
Kanakis GA, Goulis DG. Male contraception: a clinically-oriented review. Hormones (Athens). 2015;14(4):598.
Kolesinska Z, Ahmed SF, Niedziela M, Bryce J, Molinska-Glura M, Rodie M, Jiang J, Sinnott RO, Hughes IA, Darendeliler F, Hiort O, van der Zwan Y, Cools M, Guran T, Holterhus PM, Bertelloni S, Lisa L, Arlt W, Krone N, Ellaithi M, Balsamo A, Mazen I, Nordenstrom A, Lachlan K, Alkhawari M, Chatelain P, Weintrob N. Changes over time in sex assignment for disorders of sex development. Pediatrics. 2014;134(3):e710.
Krausz C, Hoefsloot L, Simoni M, Tuttelmann F. EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: state-of-the-art 2013. Andrology. 2014;2(1):5.
Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter’s syndrome. Lancet. 2004;364(9430):273.
Lenzi A, Balercia G, Bellastella A, Colao A, Fabbri A, Foresta C, Galdiero M, Gandini L, Krausz C, Lombardi G, Lombardo F, Maggi M, Radicioni A, Selice R, Sinisi AA, Forti G. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Investig. 2009;32(11):934.
Martinez-Jabaloyas JM. Hipogonadism. Global epidemiology and transversal relationships. Arch Esp Urol. 2013;66(7):632.
Matsumoto A, Bremner W. Male hypogonadism. In: Melmed S, Polonsky K, Larsen P, Kroneneberg H, editors. Williams textbook of endocrinology. Philadelphia: Saunders; 2011. p. 709–55.
McKinlay JB, Link CL. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. Eur Urol. 2007;52(2):389.
Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl. 2005;28(3):125.
Paduch DA, Skoog SJ. Diagnosis, evaluation and treatment of adolescent varicocele. ScientificWorldJournal. 2004;4(Suppl 1):263–7.
Pasqualini RQ, Bur G. Hypoandrogenic syndrome with spermatogenesis. Fertil Steril. 1955;6:2.
Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients – 2002 update. Endocr Pract. 2002;8(6):440.
Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. Asian J Androl. 2007;9(2):147.
Rey RA, Grinspon RP, Gottlieb S, Pasqualini T, Knoblovits P, Aszpis S, Pacenza N, Stewart Usher J, Bergada I, Campo SM. Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. Andrology. 2013;1(1):3.
Rogol AD. Drugs of abuse and the adolescent athlete. Ital J Pediatr. 2010;36:1.
Scriven PN, Flinter FA, Braude PR, Ogilvie CM. Robertsonian translocations – reproductive risks and indications for preimplantation genetic diagnosis. Hum Reprod. 2001;16(11):2267.
Seftel AD. Male hypogonadism. Part I: epidemiology of hypogonadism. Int J Impot Res. 2006;18(2):115.
Stamou MI, Cox KH, Crowley Jr WF. Discovering genes essential to the hypothalamic regulation of human reproduction using a human disease model: adjusting to life in the “-omics” era. Endocr Rev. 2016;2016(1):4.
Tapanainen JS, Vaskivuo T, Aittomaki K, Huhtaniemi IT. Inactivating FSH receptor mutations and gonadal dysfunction. Mol Cell Endocrinol. 1998;145(1–2):129.
Tüttelmann F, Nieschlag E. Classification of andrological disorders. In: Nieschlag E, Behre H, Nieschlag S, editors. Andrology. Berlin, Heidelberg: Springer Verlag; 2010. p. 87–92.
Valdes-Socin H, Salvi R, Daly AF, Gaillard RC, Quatresooz P, Tebeu PM, Pralong FP, Beckers A. Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene. N Engl J Med. 2004;351(25):2619.
Vermeulen A. Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab. 1991;73(2):221.
Visootsak J, Graham Jr JM. Klinefelter syndrome and other sex chromosomal aneuploidies. Orphanet J Rare Dis. 2006;1:1.
Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Kanakis, G.A., Goulis, D.G. (2017). Classification and Epidemiology of Hypogonadism. In: Simoni, M., Huhtaniemi, I. (eds) Endocrinology of the Testis and Male Reproduction. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-29456-8_22-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-29456-8_22-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29456-8
Online ISBN: 978-3-319-29456-8
eBook Packages: Springer Reference MedicineReference Module Medicine